S207: Efficacy and Safety of a Third Generation Cd20 Cart (Mb-106) for Treatment of Relapsed/Refractory Follicular Lymphoma (Fl)

Shadman, Mazyar; Yeung, Christina; Redman, Mary W.; Lee, S. Y.; Lee, D. H.; Ra, Schmidt; Qian, David H; Ujjani, Chaitra S.; Dezube, B.; Poh, Christina; Warren, Edus H.; Chapuis, Aude G.; Green, D.; Cowan, Anna; Cassaday, Ryan D.; Kiem, Hans–Peter; Chow, Victor A.; Gauthier, Joyce V.; Turtle, Cameron W.; Lynch, Ryan C.; Smith, Stephen D.; Gopal, Ajay K.; Maloney, David G.; Till, Bradley J.

doi:10.1097/01.hs9.0000843720.23634.a9

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cell-based immunotherapies are also being explored, including chimeric antigen receptor T cell (CAR T) therapy and bispecific T-cell engagers (BiTEs). Preliminary, single-centre studies of CD20 and CD19 directed CAR T therapy in B-cell malignancies have demonstrated high response rates for patients with WM [ 78 , 79 ]. Multicentre phase 1/2 studies for these therapies are underway (NCT05360238, NCT04450069).…”

Section: Treatment Options For Waldenström Macroglobulinemiamentioning

confidence: 99%

A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia

et al. 2022

View full text Add to dashboard Cite

Waldenström macroglobulinemia (WM) is a slowly progressing B-cell non-Hodgkin lymphoma characterized by monoclonal IgM gammopathy in the blood and infiltration of the bone marrow by clonal lymphoplasmacytic cells. As an incurable disease, the goals for therapy for WM are to relieve symptoms, slow disease progression, prevent organ damage, and maintain quality of life. However, given the rarity of WM, clinical trials comparing treatments for WM are limited and there is no definitive standard of care. The selection of first-line WM therapy is thus based on patient factors, disease characteristics, and drug access, with bendamustine-rituximab and Bruton’s tyrosine kinase (BTK) inhibitor therapy considered preferred treatments. Other treatments such as proteasome inhibitor- or purine analogue-based therapy, alternative chemoimmunotherapy, and autologous stem cell transplantation are generally reserved for the relapsed setting but may be used in rare circumstances in earlier lines of therapy. This paper summarizes the efficacy and safety of these WM therapies and discusses considerations for treatment from a Canadian perspective.

show abstract

Section: Treatment Options For Waldenström Macroglobulinemiamentioning

confidence: 99%

A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia

et al. 2022

View full text Add to dashboard Cite

show abstract

The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review

Hansen,

Liu,

Ranjan

et al. 2023

Cancers

View full text Add to dashboard Cite

Although chimeric antigen receptor (CAR)-T cell therapies are typically administered in the inpatient setting, outpatient administration is rapidly expanding. However, there is limited summarized evidence comparing outcomes between outpatient and inpatient administration. This systematic literature review aims to compare the safety, efficacy, quality of life (QoL), costs, and healthcare resource utilization (HCRU) outcomes in patients with hematological cancer who are administered CAR-T therapy in an outpatient versus an inpatient setting. Publications (2016 or later) that reported the outcomes of interest in patients treated with a CAR-T therapy in both outpatient and inpatient settings, or only the outpatient setting, were reviewed. In total, 38 publications based on 21 studies were included. Safety findings suggested the comparable frequency of adverse events in the two settings. Eleven studies that reported data in both settings showed comparable response rates (80–82% in outpatient and 72–80% in inpatient). Improvements in the QoL were observed in both settings while costs associated with CAR-T therapy were lower in the outpatient setting. Although unplanned hospitalizations were higher in the outpatient cohort, overall HCRU was lower. Outpatient administration of CAR-T therapy appears to have comparable outcomes in safety, efficacy, and QoL to inpatient administration while reducing the economic burden.

show abstract

S207: Efficacy and Safety of a Third Generation Cd20 Cart (Mb-106) for Treatment of Relapsed/Refractory Follicular Lymphoma (Fl)

Cited by 2 publications

References 0 publications

A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia

A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia

The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review

Contact Info

Product

Resources

About